Benzinga··PrnewswireViking Therapeutics Completes Enrollment in Phase 3 VANQUISH-2 Obesity Trial
Viking Therapeutics finishes enrolling 1,000 patients in Phase 3 VANQUISH-2 trial of VK2735 for obesity treatment, with results expected in 2027.
VKTXPhase 3 clinical trialobesity treatment